Gastrointestinal stromal tumor differential diagnosis
|
Gastrointestinal stromal tumor Microchapters |
|
Differentiating Gastrointestinal stromal tumor from other Diseases |
|---|
|
Diagnosis |
|
Treatment |
|
Case Studies |
|
Gastrointestinal stromal tumor differential diagnosis On the Web |
|
American Roentgen Ray Society Images of Gastrointestinal stromal tumor differential diagnosis |
|
FDA on Gastrointestinal stromal tumor differential diagnosis |
|
CDC on Gastrointestinal stromal tumor differential diagnosis |
|
Gastrointestinal stromal tumor differential diagnosis in the news |
|
Blogs on Gastrointestinal stromal tumor differential diagnosis |
|
Directions to Hospitals Treating Gastrointestinal stromal tumor |
|
Risk calculators and risk factors for Gastrointestinal stromal tumor differential diagnosis |
Editor-In-Chief: C. Michael Gibson, M.S., M.D. [1];Associate Editor(s)-in-Chief: Akshun Kalia M.B.B.S.[2]Parminder Dhingra, M.D. [3]
Overview
Around 75 % of the patients with gastrointestinal stromal tumors (GIST) are asymptomatic and the rest have non-specific symptoms such as vague abdominal pain and discomfort. Thus, GIST must be differentiated from other tumors on the basis of cell markers. GIST must be differentiated from other mesenchymal tumors such as gastrointestinal leiomyoma, gastrointestinal leiomyosarcoma, gastrointestinal carcinoma, gastrointestinal schwannoma and melanoma.
Differential Diagnosis
Around 75 % of the patients with gastrointestinal stromal tumors (GIST) are asymptomatic and the rest have non-specific symptoms such as vague abdominal pain and discomfort. Thus, GIST must be differentiated from other tumors on the basis of cell markers. GIST must be differentiated from other mesenchymal tumors such as gastrointestinal leiomyoma, gastrointestinal leiomyosarcoma, gastrointestinal carcinoma, gastrointestinal schwannoma and melanoma.[1][2][3][4]
| Marker | GIST | GI leiomyoma | GI Leiomyosarcoma | Schwannoma | GI Carcinoma | Melanoma |
|---|---|---|---|---|---|---|
| CD117 | Positive (95%) | Negative | Negative | Negative | Positive (50%) | Positive |
| CD34 | Positive (70%) | Negative | Negative | Positive (33%) | Negative | Negative |
| DOG 1 | Positive (95%) | Negative | Negative | Negative | Negative | Rare |
| Other
Markers |
Desmin positive
in 1-2% |
Desmin positive in
100% cases |
Desmin positive but
variable proportion |
GFAP positive | Keratin positive | S100 positive |
References
- ↑ West RB, Corless CL, Chen X, Rubin BP, Subramanian S, Montgomery K, Zhu S, Ball CA, Nielsen TO, Patel R, Goldblum JR, Brown PO, Heinrich MC, van de Rijn M (2004). "The novel marker, DOG1, is expressed ubiquitously in gastrointestinal stromal tumors irrespective of KIT or PDGFRA mutation status". Am. J. Pathol. 165 (1): 107–13. doi:10.1016/S0002-9440(10)63279-8. PMC 1618538. PMID 15215166.
- ↑ "Gastrointestinal stromal tumour".
- ↑ Baskin Y, Kocal GC, Kucukzeybek BB, Akbarpour M, Kayacik N, Sagol O, Ellidokuz H, Oztop I (2016). "PDGFRA and KIT Mutation Status and Its Association With Clinicopathological Properties, Including DOG1". Oncol. Res. 24 (1): 41–53. doi:10.3727/096504016X14576297492418. PMID 27178821.
- ↑ Gerhart DZ, Broderius MA, Borson ND, Drewes LR (1992). "Neurons and microvessels express the brain glucose transporter protein GLUT3". Proc. Natl. Acad. Sci. U.S.A. 89 (2): 733–7. PMC 48313. PMID 1731347.